Bio-Rad Labs (NYSE: BIO) reported Q3 EPS of $2.26, $0.31 better than the analyst estimate of $1.95. Revenue for the quarter came in at $653 million versus the consensus estimate of $652.24 million.

Full-Year 2025 Financial Outlook

Bio-Rad is maintaining its financial outlook for the full year 2025. The company continues to expect non-GAAP, currency-neutral revenue growth of approximately 0 to 1.0 percent and a non-GAAP operating margin of approximately 12.0 to 13.0 percent.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.